User profiles for "author:Alessio Aghemo"
Alessio AghemoHumanitas University Verified email at hunimed.eu Cited by 21012 |
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Background Since the release of the first global hepatitis elimination targets in 2016, and
until the COVID-19 pandemic started in early 2020, many countries and territories were …
until the COVID-19 pandemic started in early 2020, many countries and territories were …
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
GS Cooke, I Andrieux-Meyer, TL Applegate… - The lancet …, 2019 - thelancet.com
Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …
[PDF][PDF] New horizons in hepatitis C antiviral therapy with direct‐acting antivirals
A Aghemo, R De Francesco - Hepatology, 2013 - Wiley Online Library
Most direct‐acting antivirals (DAAs) that are being developed as therapy against hepatitis C
virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter …
virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter …
EASL recommendations on treatment of hepatitis C: final update of the series☆
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
[PDF][PDF] COVID-19 and liver disease
Since December 2019, patients with unexplained pneumonia have been found in Wuhan,
Hubei Province, China, which was caused by a novel coronavirus that had not been …
Hubei Province, China, which was caused by a novel coronavirus that had not been …
High rates of 30-day mortality in patients with cirrhosis and COVID-19
M Iavarone, R D'Ambrosio, A Soria, M Triolo… - Journal of …, 2020 - Elsevier
Background & Aims Coronavirus disease 2019 (COVID-19) poses a major health threat to
healthy individuals and those with comorbidities, but its impact on patients with cirrhosis is …
healthy individuals and those with comorbidities, but its impact on patients with cirrhosis is …
[PDF][PDF] A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
R D'Ambrosio, A Aghemo, MG Rumi, G Ronchi… - …, 2012 - Wiley Online Library
Although annular fibrosis is the hallmark of cirrhosis, other microscopic changes that affect
liver function such as sinusoid capillarization or loss of metabolic zonation are common. A …
liver function such as sinusoid capillarization or loss of metabolic zonation are common. A …
EASL recommendations on treatment of hepatitis C 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
Global multi-stakeholder endorsement of the MAFLD definition
N Méndez-Sánchez, E Bugianesi, RG Gish… - The lancet …, 2022 - thelancet.com
Correspondence 390 www. thelancet. com/gastrohep Vol 7 May 2022 at least two different
mechanisms of action. Views were divided on the failure of immunomodulators, with 252 …
mechanisms of action. Views were divided on the failure of immunomodulators, with 252 …
Impact of COVID-19 on global HCV elimination efforts
Background & Aims Coronavirus disease 2019 (COVID-19) has placed a significant strain
on national healthcare systems at a critical moment in the context of hepatitis elimination …
on national healthcare systems at a critical moment in the context of hepatitis elimination …